These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32277344)

  • 1. Comparable Effect of Two-Step Versus Extended Infusions on the Pharmacokinetics of Imipenem in Patients with Sepsis and Septic Shock.
    Huang Y; Xu K; Zhan Y; Zha X; Liu S; Xie J; Liu L; Li Q; Shao H; Yang Y
    Adv Ther; 2020 May; 37(5):2246-2255. PubMed ID: 32277344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Pathophysiology and Volume of Distribution Among Patients With Sepsis or Septic Shock Treated With Imipenem: A Prospective Cohort Study.
    Huang Y; Yang J; Xie J; Liu L; Liu S; Guo F; Qiu H; Yang Y
    J Infect Dis; 2020 Mar; 221(Suppl 2):S272-S278. PubMed ID: 32176787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.
    Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H
    Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
    Kotapati S; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.
    Couffignal C; Pajot O; Laouénan C; Burdet C; Foucrier A; Wolff M; Armand-Lefevre L; Mentré F; Massias L
    Br J Clin Pharmacol; 2014 Nov; 78(5):1022-34. PubMed ID: 24903189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion.
    Jaruratanasirikul S; Raungsri N; Punyo J; Sriwiriyajan S
    J Antimicrob Chemother; 2005 Dec; 56(6):1163-5. PubMed ID: 16234333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
    Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is continuous infusion of imipenem always the best choice?
    Suchánková H; Lipš M; Urbánek K; Neely MN; Strojil J
    Int J Antimicrob Agents; 2017 Mar; 49(3):348-354. PubMed ID: 28189734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
    Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
    Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.
    Jaruratanasirikul S; Vattanavanit V; Wongpoowarak W; Nawakitrangsan M; Samaeng M
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):735-747. PubMed ID: 32886347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial.
    De Winter S; Wauters J; Meersseman W; Verhaegen J; Van Wijngaerden E; Peetermans W; Annaert P; Verelst S; Spriet I
    Int J Antimicrob Agents; 2018 Apr; 51(4):562-570. PubMed ID: 29180278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia.
    Jaruratanasirikul S; Wongpoowarak W; Jullangkoon M; Samaeng M
    J Pharmacol Sci; 2015 Feb; 127(2):164-9. PubMed ID: 25727953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria.
    Kothekar AT; Divatia JV; Myatra SN; Patil A; Nookala Krishnamurthy M; Maheshwarappa HM; Siddiqui SS; Gurjar M; Biswas S; Gota V
    Ann Intensive Care; 2020 Jan; 10(1):4. PubMed ID: 31925610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?
    Marsot A
    J Pharm Pharm Sci; 2020; 23():470-485. PubMed ID: 33227230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit.
    Jaruratanasirikul S; Boonpeng A; Nawakitrangsan M; Samaeng M
    Pharmacotherapy; 2021 Jul; 41(7):572-597. PubMed ID: 34080708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.